Recovery & Tissue Repair · Reviewed by Ian K. Tseng, MD

What Is BPC-157? The Pentadecapeptide, Explained

BPC-157 is one of the most searched compounds in the peptide space, and one of the most confidently discussed by people citing research they have not read. The mechanism is genuinely interesting, the evidence base is thinner than the internet suggests, and the regulatory picture changed substantially in 2026. Here is the honest version of all three.

Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director

What the compound is

BPC stands for "Body Protection Compound." The peptide is a synthetic fifteen-amino-acid sequence corresponding to a portion of a protein identified in human gastric juice. The original research interest came from the observation that the gastrointestinal tract maintains a remarkable capacity for self-repair in a chemically hostile environment, and the question of what mediates that.

Proposed mechanisms in the literature include effects on angiogenesis — the formation of new blood vessels — modulation of growth factor expression, and interaction with nitric oxide signaling pathways. These are plausible and interesting mechanisms.

What the evidence actually consists of

This is where careful reading matters. The substantial majority of published BPC-157 research is preclinical: rodent models, isolated tissue preparations, and in vitro work. The findings in those models are frequently striking, which is a large part of why the compound developed the reputation it has.

Well-controlled human clinical trials establishing efficacy and safety for the uses discussed online are, at the time of writing, largely absent. That is not a claim that the compound does nothing. It is a statement about the state of the evidence: animal data is a reason to investigate further, not a substitute for human trials. Many compounds with impressive rodent results have not replicated in humans.

Anyone presenting BPC-157 as an established, evidence-backed therapy for human tissue repair is describing a body of research that does not currently exist in that form.

A regulatory status that moved in 2026

BPC-157's compounding status has changed materially, and much of what is written online predates the change. The timeline is worth stating precisely.

In 2023 the FDA placed BPC-157 in Category 2 of the 503A Bulks List — the designation for substances raising significant safety risks — citing limited safety data and insufficient characterization. For roughly two and a half years, that placement was the reason legitimate compounding pharmacies would not prepare it.

On April 22, 2026 the FDA removed BPC-157, along with eleven other peptides, from Category 2. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted to recommend BPC-157 for inclusion on the 503A Bulks List, by a margin of 8 to 6 with one abstention.

One clarification matters and is frequently glossed over: a PCAC recommendation is advisory, not binding. Formal inclusion on the bulks list requires FDA notice-and-comment rulemaking, which typically takes a year or more, and the agency has departed from committee recommendations before. The accurate description of BPC-157 today is a compounded preparation that is not FDA-approved, no longer sits in the FDA's significant-safety-risk category, and carries a favorable advisory recommendation with final rulemaking still pending.

Compounded is not the same as approved

BPC-157 is prepared as a compounded medication. It has not been through FDA pre-market review, and it does not carry an approved label, an approved indication, or approved dosing guidance. That is an accuracy point about the regulatory category, and it is one a physician should state plainly during consent rather than leave for a patient to discover.

This is a different thing from the gray market. The distinction is not the molecule — it is whether a licensed physician evaluated you, whether a licensed pharmacy prepared it against a prescription, and whether anyone is monitoring what happens next.

What the gray market is actually selling

BPC-157 is easy to buy online from vendors operating outside the prescription framework, under a "for research use only" or "not for human consumption" label. That labeling is the legal position that permits the sale — it is not a formality.

What arrives is a vial with no prescription, no physician evaluation, no purity standard verified for human administration, no dosing guidance grounded in human data, and no one accountable for an adverse reaction. A Certificate of Analysis confirms the contents of the bottle; it does not evaluate whether your body should receive them.

We covered this distinction at length in are peptides safe? It is the clearest line between a medical program and a research-chemical purchase, and it holds regardless of what the compounding status happens to be in any given year.

How clinicians who prescribe it approach it

In clinical literature and practice, BPC-157 is framed as an adjunct to standard care — rest, rehabilitation, physical therapy, and proper diagnostic evaluation — rather than a replacement for any of them. Any approach that encourages skipping imaging on a joint injury is not a protocol; it is an avoidance strategy.

It is generally described in defined cycles rather than continuous use, with the target symptom or function tracked from baseline so response can actually be assessed at the end of a cycle. It is frequently discussed alongside TB-500 in the recovery literature.

The clearest contraindication is active malignancy or a history of it: the proposed mechanisms are pro-angiogenic and pro-repair, which is the wrong signal in the presence of cancer. Pregnancy and breastfeeding are also exclusions. Baseline bloodwork including a comprehensive metabolic panel is standard before any growth- or repair-signalling therapy — our bloodwork explainer covers what a physician reviews and why.

Whether any of this is relevant to your situation is a question for a licensed physician who has evaluated you individually.

How a prescribing clinician structures it

Must be true before anything starts

• ✓The injury or indication is confirmed — standard evaluation and imaging are not bypassed
• ✓No active malignancy and no history of it (the mechanisms are pro-angiogenic and pro-repair)
• ✓Not pregnant or breastfeeding
• ✓Baseline comprehensive metabolic panel reviewed, plus whatever the indication warrants

Then, in defined cycles

1Record the target symptom or function at baseline — pain, range of motion, strength, GI symptoms

2Start one agent at a time, so any reaction is attributable to something

3Run a defined course rather than open-ended use

4Follow up during the cycle, not only at the end of it

5Reassess against that recorded baseline before deciding whether to repeat

The cycle ends, then it is reassessed. Continuous open-ended use removes the only checkpoint that tells you whether it did anything.

Related reading

• What Is TB-500
• What Is GHK-Cu
• Are Peptides Safe?
• How the Soothe IV peptide therapy program works

Frequently asked questions

This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available nationwide via telehealth; prescriptions are issued by physicians licensed in your state.